

FIGURE 1H




FIGURE 2A





FIGURE 2E




WO 2005/042032

7/14

FIGURE 2F


1 2 3 4 5 6 7 kDa -66RAGE - -46 S100b - -14.3 β-actin - -46 0 3 7 10 14 21 21 (with sRAGE)

FIGURE 2G





BEST AVAILABLE COPT

FIGURE 3A































FIGURE 6A



WO 2005/042032 PCT/US2004/036170

14/14

FIGURE 6B




FIGURE 6C

